http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108042552-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-455 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-455 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 |
| filingDate | 2017-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108042552-B |
| titleOfInvention | A pharmaceutical composition comprising aescin B or its sodium salt and nicotinic acid |
| abstract | The invention discloses a pharmaceutical composition for treating ischemic stroke, which consists of aescin B or sodium salt thereof and nicotinic acid, wherein the weight ratio of the aescin B or the sodium salt thereof to the nicotinic acid is 2-20: 0.5-5. The composition provided by the invention can reduce the neurological impairment degree and mortality of an animal model with cerebral ischemia reperfusion injury, reduce the infarct volume and brain water content caused by cerebral ischemia, obviously improve the activity of SOD in rat brain tissues, reduce the generation of MDA, protect cell membranes from being damaged by free radicals, improve the activity of LDH in ischemic brain tissues and reduce the accumulation of lactic acid, and is an ideal medicament for treating ischemic stroke. |
| priorityDate | 2017-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 85.